Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 2Waldenstrom Macroglobulinemia 1Precancerous Conditions 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cyclophosphamide 3sargramostim 2ibrutinib 2Rituximab 2Peripheral Blood Stem Cell Transplantation 2Filgrastim 2zanubrutinib 1obinutuzumab 1motesanib diphosphate 1ledipasvir, sofosbuvir drug combination 1ibritumomab tiuxetan 1fludarabine phosphate 1alethine 1XELOX 1Valproic Acid 1Thalidomide 1Radiotherapy 1Psychiatric Rehabilitation 1Pharmacogenomic Testing 1Melphalan 1Leukapheresis 1Ketamine 1Interferon-alpha 1Indium 1Ifosfamide 1Gemcitabine 1Etoposide 1Dexamethasone 1Cytarabine 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Waldenstrom Macroglobulinemia × alethine × Clear all
NCT00041379 2013-12-18

Beta Alethine in Treating Patients With Waldenstrom's Macroglobulinemia

National Cancer Institute (NCI)

Phase 1/2 Unknown
Lymphoid

Lymphoma, Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡